News
VCEL
40.74
+1.72%
0.69
Weekly Report: what happened at VCEL last week (0928-1002)?
Weekly Report · 2d ago
Weekly Report: what happened at VCEL last week (0921-0925)?
Weekly Report · 09/28 10:24
Why the Pentagon Keeps Funding This Small Cap (Nasdaq: MDWD)
TipRanks · 09/22 12:30
Weekly Report: what happened at VCEL last week (0914-0918)?
Weekly Report · 09/21 10:24
Leerink Partners Sticks to Their Buy Rating for Vericel (VCEL)
TipRanks · 09/18 12:35
Vericel: MACI And Regenerative Knee Cartilage
Seeking Alpha · 09/15 03:47
Weekly Report: what happened at VCEL last week (0907-0911)?
Weekly Report · 09/14 10:30
Weekly Report: what happened at VCEL last week (0831-0904)?
Weekly Report · 09/07 10:23
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (DNA) and Vericel (VCEL)
TipRanks · 09/04 11:30
Weekly Report: what happened at VCEL last week (0824-0828)?
Weekly Report · 08/31 10:31
Weekly Report: what happened at VCEL last week (0817-0821)?
Weekly Report · 08/24 10:32
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 08/20 11:40
Weekly Report: what happened at VCEL last week (0810-0814)?
Weekly Report · 08/17 10:33
3 Major Earnings Winners You May Have Missed
NASDAQ · 08/10 12:40
Weekly Report: what happened at VCEL last week (0803-0807)?
Weekly Report · 08/10 10:27
Weekly Report: what happened at VCEL last week (0727-0731)?
Weekly Report · 08/03 10:26
TD Cowen Maintains Buy on Vericel, Raises Price Target to $58
Benzinga · 07/31 17:46
Vericel Is Maintained at Buy by TD Cowen
Dow Jones · 07/31 17:41
Vericel Price Target Raised to $58.00/Share From $54.00 by Truist Securities
Dow Jones · 07/31 13:40
Truist Securities Reiterates Buy on Vericel, Raises Price Target to $58
Benzinga · 07/31 13:30
More
Webull provides a variety of real-time VCEL stock news. You can receive the latest news about Vericel through multiple platforms. This information may help you make smarter investment decisions.
About VCEL
Vericel Corporation is a provider of advanced therapies for sports medicine and severe burn care markets. It has a differentiated portfolio of cell therapy and specialty biologic products. It markets three products in the United States. MACI (autologous cultured chondrocytes on porcine collagen membrane) is an autologous-cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The Company also holds a license for North American rights to NexoBrid (anacaulase-bcdb), a biological orphan product containing proteolytic enzymes, which is indicated for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.